+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pomalyst

  • ID: 4775165
  • Report
  • 21 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Pomalyst (pomalidomide; Celgene) is an oral class I thalidomide analog, immunomodulatory drug with antineoplastic activity.

In vitro studies have shown that the drug acts through multiple mechanisms. Evidence suggests that in addition to anti-angiogenic effects, Pomalyst inhibits proliferation and induces apoptosis of hematopoietic tumor cells, and may have antineoplastic effects. Pomalyst also enhanced T cell- and natural killer cell-mediated immunity and inhibited production of pro-inflammatory cytokines by monocytes.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Pomalyst : Multiple myeloma

LIST OF FIGURES
Figure 1: Pomalyst for multiple myeloma – SWOT analysis
Figure 2: The authors drug assessment summary of Pomalyst for multiple myeloma
Figure 3: The authors drug assessment summary of Pomalyst for multiple myeloma
Figure 4: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Pomalyst drug profile
Table 2: Pomalyst pivotal trial data in multiple myeloma
Table 3: Pomalyst late-phase trial data in multiple myeloma
Table 4: Pomalyst key ongoing clinical trials in multiple myeloma
Table 5: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Patients treated with Pomalyst across the US, Japan, and five major EU markets, by country, 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll